Bringing mass spectrometry into the care of patients with multiple myeloma.

Abstract

Serum protein electrophoresis methods are widely employed to detect, quantify and isotype M-proteins for multiple myeloma patients. Increasing clinical demands to detect residual disease and interferences from new therapeutic monoclonal antibody treatments have stretched electrophoretic methods to their analytical limits. Newer techniques to detect M-proteins using mass spectrometry (MS) are emerging with improved clinical and analytical performance. These techniques are beginning to gain traction within the routine clinical lab testing. This review describes these MS methods with attention to the current and future roles such testing could play in the care of multiple myeloma patients.

• Authors: David L Murray
• Journal: International journal of hematology (Int J Hematol) Vol. 115 Issue 6 Pg. 790-798 (Jun 2022) ISSN: 1865-3774 [Electronic] Japan
• PMID: 35471500 (Publication Type: Journal Article, Review)
• Copyright: © 2022. Japanese Society of Hematology.

Chemical References

• Antibodies, Monoclonal

Topics

• Antibodies, Monoclonal (therapeutic use)
• Humans
• Multiple Myeloma (diagnosis, therapy)
• Neoplasm, Residual
• Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (methods)